BioLine RX Ltd
TASE:BLRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioLine RX Ltd
Total Equity
BioLine RX Ltd
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Total Equity
$19.5m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-9%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Total Equity
$269.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Total Equity
$17.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Total Equity
-$105.5m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Total Equity
$15.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Total Equity
-$14.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
BioLine RX Ltd
Glance View
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which focuses on oncology. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
See Also
What is BioLine RX Ltd's Total Equity?
Total Equity
19.5m
USD
Based on the financial report for Sep 30, 2025, BioLine RX Ltd's Total Equity amounts to 19.5m USD.
What is BioLine RX Ltd's Total Equity growth rate?
Total Equity CAGR 10Y
-9%
Over the last year, the Total Equity growth was 130%. The average annual Total Equity growth rates for BioLine RX Ltd have been -29% over the past three years , -5% over the past five years , and -9% over the past ten years .
